<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Liver-directed therapy for <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> includes: intra-arterial techniques such as transarterial chemoembolization (TACE) and <z:chebi fb="2" ids="33331">yttrium</z:chebi>-90 resin ((90)Y) microsphere radioembolization and ablative technologies: cryoablation, radiofrequency ablation, and microwave ablation </plain></SENT>
<SENT sid="1" pm="."><plain>Combining embolization techniques with liver ablation may enhance the therapeutic benefit of each and result in improved patient survival </plain></SENT>
<SENT sid="2" pm="."><plain>We retrospectively reviewed our experience with combined intra-arterial therapies and ablation for unresectable hepatic colorectal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from 1996 to 2011 </plain></SENT>
<SENT sid="3" pm="."><plain>Patient demographics, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> characteristics, specific liver-directed treatments, procedure-related morbidity and mortality, and overall survival were recorded </plain></SENT>
<SENT sid="4" pm="."><plain>There were 17 (53%) males and 15 (47%) females </plain></SENT>
<SENT sid="5" pm="."><plain>Average age for the group was 74.1 years (median, 75.5 years) </plain></SENT>
<SENT sid="6" pm="."><plain>Fifteen patients (46.9%) had a single <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Eleven (34%) patients had bilobar <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> distribution and seven (22%) patients had vascular invasion of the portal vein or hepatic/caval venous structures </plain></SENT>
<SENT sid="8" pm="."><plain>Seven (21%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were greater than 5 cm in diameter </plain></SENT>
<SENT sid="9" pm="."><plain>Twenty-seven (84.4%) patients received TACE and five (15.6%) received (90)Y </plain></SENT>
<SENT sid="10" pm="."><plain>Fourteen (43%) were embolized before any ablation </plain></SENT>
<SENT sid="11" pm="."><plain>Fifty-three per cent of patients required multiple hepatic ablation sessions </plain></SENT>
<SENT sid="12" pm="."><plain>Median length of hospital stay was 1 day </plain></SENT>
<SENT sid="13" pm="."><plain>There were no procedure-related mortalities and complications occurred in six (18.8%) patients </plain></SENT>
<SENT sid="14" pm="."><plain>Mean follow-up for the group was 33 months </plain></SENT>
<SENT sid="15" pm="."><plain>Kaplan-Meier 1-, 3-, and 5-year estimated survival was 93.8, 50.0, and 10.1 per cent, respectively </plain></SENT>
<SENT sid="16" pm="."><plain>Median survival for the group was 46 months </plain></SENT>
<SENT sid="17" pm="."><plain>Hepatic ablation and embolization techniques can be combined safely with minimal morbidity </plain></SENT>
<SENT sid="18" pm="."><plain>In our series, we observed 5-year survival in 10 per cent of patients </plain></SENT>
</text></document>